X4 Pharmaceuticals presents data from its Phase 2 trial of mavorixafor

X4 Pharmaceuticals (XFOR) announced the presentation of positive data from its completed Phase 2 trial of mavorixafor in the treatment of certain chronic neutropenic, CN, conditions at the 30th Annual Congress of the European Hematology Association, EHA, in Milan, Italy. The Phase 2 study of oral, once-daily mavorixafor was a six-month, open-label clinical trial that enrolled a total of 23 participants diagnosed with idiopathic, congenital, or cyclic chronic neutropenia, and had two subsets: mavorixafor monotherapy and mavorixafor in combination with injectable G-CSF. The two poster presentations at EHA today focused on clinical results based on the following goals of the study: Assessing safety and the ability of oral, once-daily mavorixafor to sustainably raise absolute neutrophil count as a monotherapy and in combination with injectable G-CSF; and Assessing whether treatment of participants with mavorixafor could enable the reduction of G-CSF dosage while maintaining clinically targeted ANC levels and physicians’ willingness to do so.